Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 8Neoplasms, Plasma Cell 3Lymphoma, Non-Hodgkin 3Prostatic Neoplasms 2Pancreatic Neoplasms 2Smoldering Multiple Myeloma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Ovarian Neoplasms 1Neoplasms by Histologic Type 1Neoplasms 1Multi-centric Castleman's Disease 1Monoclonal Gammopathy of Undetermined Significance 1Macular dystrophy, corneal type 1 1Lymphoma 1Lung Neoplasms 1Head and Neck Neoplasms 1Cytokine Release Syndrome 1Colorectal Neoplasms 1Castleman Disease 1Carcinoma, Renal Cell 1

Interventions

Peripheral Blood Stem Cell Transplantation 4Epoetin Alfa 3Darbepoetin alfa 3Cyclophosphamide 3liposomal amphotericin B 2fludarabine phosphate 2Microarray Analysis 2Methylprednisolone 2Interferon-alpha 2In Situ Hybridization, Fluorescence 2Filgrastim 2Cytogenetic Analysis 2Cyclosporine 2Caspofungin 2Bortezomib 2Antilymphocyte Serum 2tanespimycin 1siltuximab 1pyroxamide 1piperine 1ibrutinib 1ferrous sulfate 1ferric gluconate 1aldesleukin 1Whole-Body Irradiation 1Watchful Waiting 1Urination 1Topotecan 1Therapeutics 1Tacrolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Monoclonal Gammopathy of Undetermined Significance × siltuximab × Clear all
NCT01219010 2015-01-19

A Study Evaluating the Effects of Siltuximab on the Heart in Patients With Monoclonal Gammopathy of Undetermined Significance, Smoldering Multiple Myeloma, or Indolent Multiple Myeloma

Janssen Research & Development, LLC

Phase 1 Completed
30 enrolled
Plasma cell

Smoldering Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance, Multiple Myeloma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡